Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from BTIG Research

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $16.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 246.70% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. Roth Capital reiterated a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a research report on Monday, August 24th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Finally, Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Price Performance

Shares of COYA traded down $0.03 on Tuesday, reaching $4.62. The company’s stock had a trading volume of 101,731 shares, compared to its average volume of 181,283. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75. The stock has a market capitalization of $108.26 million, a P/E ratio of -4.29 and a beta of 0.61. The stock’s 50 day simple moving average is $4.66 and its two-hundred day simple moving average is $4.66.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Analysts expect that Coya Therapeutics will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP grew its holdings in Coya Therapeutics by 1,200.0% during the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after buying an additional 12,000 shares in the last quarter. AXQ Capital LP bought a new stake in shares of Coya Therapeutics during the second quarter valued at approximately $116,000. Cetera Investment Advisers lifted its holdings in shares of Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after buying an additional 8,000 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Coya Therapeutics during the first quarter worth $161,000. Finally, Long Corridor Asset Management Ltd bought a new position in shares of Coya Therapeutics during the fourth quarter worth $225,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.